Fulgent Genetics vs Schrodinger
Fulgent Genetics is the larger business, with $323m of revenue in fiscal 2025 against $256m for Schrodinger (1.3 times as much). Schrodinger grew faster (23.3% against 13.8%). Fulgent Genetics kept more of each dollar of sales as profit: a net margin of -18.8% against -40.4%. Schrodinger carries less debt relative to equity (0.0% against 0.2%).
| Latest fiscal year | Fulgent GeneticsFLGT, 2025 | SchrodingerSDGR, 2025 |
|---|---|---|
| Revenue | $323m | $256m |
| Revenue growth | 13.8% | 23.3% |
| Net income | −$60.5m | −$103m |
| Operating margin | -28.2% | -65.2% |
| Net margin | -18.8% | -40.4% |
| Return on equity | -5.4% | -26.3% |
| Free cash flow | −$124m | $12.5m |
| Cash | $50.2m | $231m |
| Total debt | $2.4m | $0 |
| Debt to equity | 0.2% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | $10.9m | — |
| Employees | — | 850 |
| Market value | $531m | $2.05bn |
| Price vs our value range | — | — |
| Moat score | 23 (Weak) | 28 (Weak) |
| Insider trades, 12 months | 0 buys, 15 sales | 0 buys, 20 sales |